The first aim of the study was to determine the tissue-specific distribution of two molecules that are thought to play a crucial function in the interaction between EPDCs and other cardiac tissues, namely the Wilms' Tumor transcription factor (WT1) and retinaldehyde-dehydrogenase2 (RALDH2). This study was performed in normal avian and in quail-to-chick chimeric embryos. It was found that EPDCs that maintain the expression of WT1 and RALDH2 initially populate the subepicardial space and subsequently invade the ventricular myocardium. As EPDCs differentiate into the smooth muscle and endothelial cell lineage of the coronary vessels, the expression of WT1 and RALDH2 becomes downregulated. This process is accompanied by the upregulation of lineage-specific markers. We also observed EPDCs that continued to express WT1 (but very little RALDH2) which did not contribute to the formation of the coronary system. A subset of these cells eventually migrates into the atrioventricular (AV) cushions, at which point they no longer express WT1. The WT1/ RALDH2-negative EPDCs in the AV cushions do, however, express the smooth muscle cell marker caldesmon. The second aim of this study was to determine the impact of abnormal epicardial growth on cardiac development. Experimental delay of epicardial growth distorted normal epicardial development, reduced the number of invasive WT1/RALDH2-positive EPDCs, and provoked anomalies in the coronary vessels, the ventricular myocardium, and the AV cushions. We suggest that the proper development of ventricular myocardium is dependent on the invasion of undifferentiated, WT1-positive, retinoic acid-synthesizing EPDCs. Furthermore, we propose that an interaction between EPDCs and endocardial (derived) cells is imperative for correct development of the AV cushions. © 2002 Elsevier Science (USA)
INTRODUCTION
The primitive cardiac tube initially consists of two concentric layers of cells: an inner endothelial layer, better known as the endocardium, and an outer layer formed by primitive myocardial cells (reviewed in Wessels and Markwald, 2000) . Both layers are separated by an extracellular matrix-rich, acellular space, commonly referred to as the cardiac jelly. After completion of cardiac looping, a third layer of cells appears on the myocardial surface of the heart. This epithelial layer is known as the epicardium (Viragh and Challice, 1973) . Whereas both the endocardium and myocardium differentiate from the precardiac mesoderm of the original heart fields (Tam and Schoenwolf, 1999; Lough and Sugi, 2000; Wessels and Markwald, 2000) , the epicardial cells derive from an extracardiac source of coelomic origin, the proepicardium (Viragh and Challice 1981; Viragh et al., 1993; Mä nner et al., 2001) .
After the formation of the epicardium (Ho and Shimada, 1978; Komiyama et al., 1987; Hiruma and Hirakow, 1989; Hirakow, 1992) , an epithelial-to-mesenchymal (EMT) transformation of a subset of epicardial cells (epicardial EMT) results in the generation of epicardially derived cells (EPDCs), which initially migrate into the subepicardial space. In vitro epicardial EMT reportedly can be induced by several growth factors, including epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) (Dettman et al., 1998; Morabito et al., 2001) . Local accumulation of EPDCs in the subepicardial space of junctional areas of the heart occurs; these regions include the interventricular sulcus, the atrioventricular (AV) junction, and conoventricular (CV) grooves.
The developmental fate of EPDCs can be studied by using several techniques. In particular, the quail-to-chick chimera approach (transplantation of a quail proepicardium onto a chick host heart) has been proven extremely informative. This technique allows the immunohistochemical identification of virtually all (pro)epicardially derived quail donor cells with a quail-specific antibody (QCPN), while at the same time characterizing their state of differentiation by using cell type-specific (e.g., endothelial and smooth muscle cell) antibodies. The above-mentioned studies have demonstrated that, after their formation, a subpopulation of EPDCs migrates into myocardial tissues (specifically the AV and ventricular myocardium) and differentiates in situ into interstitial fibroblasts, coronary smooth muscle cells, and coronary endothelium (Pé rez-Pomares et al., 1997 Dettman et al., 1998; Gittenberger-de Groot et al., 1998; Mä nner, 1999) . The quail-to-chick chimera studies have also demonstrated that a subset of EPDCs has the ability to migrate through the myocardial wall of the developing heart to finally populate the mesenchymal tissue of the AV endocardial cushions. Interestingly, it appears that EPDCs do not migrate into the endocardial cushions of the outflow tract (Mä nner, 1999) .
In recent years, a series of markers have been described that might provide more insight into the cell biology of the epicardial and epicardially derived cell. The novel cell adhesion molecule bves is expressed in the proepicardium, epicardium, and EPDCs (Reese and Bader, 1999; Wada et al., 2001 ) and seems to play an important role in epicardial cell-cell interactions. Other factors preferentially expressed in epicardial cells and of crucial importance for normal cardiac development are FOG2 (Tevosian et al., 2000) , alpha-4 integrin (Yang et al., 1995; Pinco et al., 2001) , epicardin/capsulin (Hidai et al., 1998; Robb et al., 1998) , and Wilms' tumor transcription factor (WT1; Moore et al., 1999) .
In this paper, we specifically focus on the tissue distribution of two epicardially expressed molecules that may play a crucial role in the interaction between EPDCs and other cardiac tissues, namely WT1 and retinaldehydedehydrogenase2 (RALDH2). In a previous study, we demonstrated strong cardiac expression of WT1 restricted to the late proepicardial stage (H/H18), the developing epicardium, and presumptive EPDCs in avian embryos (Carmona et al., 2001) . WT1 expression has also been described in the developing epicardium in the mouse (Moore et al., 1998) . The WT1 gene encodes for a zincfinger transcription factor reported to be related with normal cell division and differentiation (Armstrong et al., 1993) . WT1 putative targets seem to be multiple, including the genes of some receptors for retinoic acid (RA) and insulin-like growth factor1 (IGF1), as well as other growth factor genes like the IGF2 or the platelet-derived growth factor-A (PDGF-A) . WT1 knockout (k.o.) mice are characterized by underdevelopment of the urogenital system (Kreidberg et al., 1993) and by an abnormally developed epicardium with greatly reduced numbers of EPDCs combined with perturbation of coronary system (Moore et al., 1999) . Although WT1 is only expressed in the epicardium and related cells, the k.o. embryos eventually die because of severe impairment of myocardial development resulting in pericardial hemorrhage (Moore et al., 1999) .
RALDH2 is a key enzyme in the synthesis of retinoic acid (McCaffery and Drä ger, 1995) and is expressed in primitive avian (Xavier-Neto et al., 2000) and murine (Moss et al., 1998) epicardium but not in myocardial or endocardial cells. The role of retinoic acid (RA), its receptors, and related molecules in cardiac development is complex and has not been elucidated completely. In the case of RALDH2, it has been postulated that its RA synthetic activity is related to muscular differentiation as RALDH2-producing mesenchyme invades myogenic populations (Berggren et al., 2001) . Cardiac developmental defects can be induced by depriving the heart of RA as well as by exposing the heart to increased levels of RA. Cardiac defects are also found in the retinoic acid X receptor (RXR)-alpha k.o. mouse (Gruber et al., 1996) . One of the features of the RXR-alpha k.o. mouse is a characteristic hypoplastic compact ("thin") myocardial layer (Dyson et al., 1995) that closely resembles the myocardial phenotype of the WT1-defective mouse.
All the observations related to the experimental or genetic disruption of epicardial development strongly suggest that the epicardium and the EPDCs play a very important role in cardiac development. Indeed, a series of studies show that experimental and genetic perturbation of epicardial development leads to severe anomalies in myocardial and coronary development. (Mä nner, 1993; Kwee et al., 1995; Yang et al., 1995; Moore et al., 1999; Gittenberger-de Groot et al., 2000) . Very little is known, however, about the cellular and molecular mechanisms involved in the interaction between EPDCs and other tissues in the heart during cardiogenesis.
In this paper, we describe the origin and fate of EPDCs in normal avian and quail-to-chick chimeric embryos using RALDH2, WT1, and a panel of "tissue-specific"/ differentiation markers. These markers included cytokera-tin (CK), a good marker for early epicardial development (Vrancken Peeters et al., 1995; Pé rez-Pomares et al., 1997) , QCPN, a quail-specific antibody, QH1 specific for quail (hem)angioblasts (Pardanaud et al., 1987) , and caldesmon/ smooth muscle alpha-actin as markers for smooth muscle cells and related cell types (Mikawa and Gourdie, 1996) . We then moved to experimental in ovo models to disrupt epicardial development (proepicardial ablations and proepicardial block) to analyze in detail how perturbation of EPDC development interferes with cardiac development.
MATERIALS AND METHODS
The animals used in this study were handled in compliance with the Guide for the Care and Use of Laboratory animals published by the U.S. National Institutes of Health (NIH). Chick and quail eggs were kept in an incubator at 37°C. The avian embryos were staged according to Hamburger and Hamilton (1951) .
Proepicardial Quail/Chick Chimeras
Quail-to-chick proepicardial chimeras were essentially prepared as previously described (Mä nner, 1999) with the following modifications: Host chick embryos were incubated until stages H/H16 -H/H17. At this point, the eggs were carefully windowed. Using sharpened tungsten needles, small openings were made through the vitelline and chorionic membranes to expose the pericardial cavity. For each embryo, a small piece of the eggshell membrane was cut with iridectomy scissors and made to fit exactly between the sinoatrial sulcus and the caudal vitelline veins. Then, stage H/H16 -H/H17 quail embryo donors were excised and perfused with EBSS (GIBCO). The heart was removed by cutting it through the outflow tract and the sinoatrial sulcus. The previously prepared eggshell membrane was introduced through the omphalomesenteric vein of the quail embryo and pushed until it reached the cardiac lumen, so that the sinus venosus formed a cuff around the membrane, holding the donor proepicardium on its surface (see Fig.  2B ). The membrane carrying the quail (donor) proepicardium was inserted facing the ventricular heart surface. After the operation, the eggs were sealed with Scotch tape and reincubated to obtain H/H25-H/H26 (2 chimeras, 96 -108 h of incubation), H/H28 -H/ H29 (4 chimeras, 132-144 h of incubation), or H/H32 (2 chimeras, 180 h of incubation). Four chimeras were fixed in modified Amsterdam's Fixative (methanol:acetone:water ϭ 2:2:1), dehydrated in a graded series of ethanol, cleared in toluene, carefully oriented, and embedded in paraffin (Paraplast Plus, OXFORD Labware, St. Louis). Finally, 5-m serial sections were mounted on microscope slides (Superfrost/Plus, Fisherbrand, Fisher Scientific, Pittsburgh, PA). For cryostat sections, four chimeras were processed as described for WT1 immunohistochemistry. 
FIG. 2.
Quail-to-chick chimeras. Cartoons in (A-C) depict the basic steps of the quail-to-chick proepicardial transplantation. As shown, the entire quail proepicardium from stage H/H16 -H/H17 is transplanted together with a piece of the sinus venosus (all in green) by using a piece of eggshell membrane as a carrier (in blue). In (B), the specific location of the explant is shown. 
Immunohistochemistry
The normal expression pattern of WT1 was studied in a series of Japanese quail embryos (Coturnix coturnix japonica) ranging from stages H/H18 to H/H30 and in chick embryos (Gallus gallus) of stages H/H18 -H/H31. For WT1 immunohistochemistry, the embryos were excised and cryoprotected in 10, 20, and 30% sucrose solutions in TPBS (Tris phosphate-buffered saline), where they were kept at 4°C until they sunk. Then, the embryos were embedded in OCT-embedding media (TissueTek) and snap-frozen in liquid nitrogen-cooled isopentane. Sections (10 -14 m) were obtained in a cryostat, collected on poly-L-lysine-coated slides, and fixed for 10 min in 1:1 methanol/acetone solution at Ϫ20°C. Sections were rehydrated in TPBS and nonspecific binding sites were saturated for 30 min with 4% normal goat serum, 1% bovine serum albumin, and 0.1% Triton X-100 in PBS (GBT). The slides were incubated overnight at 4°C by using a polyclonal anti-human WT1 (Santa Cruz, C-19) antibody diluted 1:50 in PBS (0.04 mg IgG/ml) followed by an incubation (1 h, room temperature) in a secondary biotin-conjugated anti-rabbit goat IgG (Sigma) diluted 1:100 in GBT. Then, the sections were incubated for 1 h in extravidin-peroxidase complex (Sigma) diluted 1:150 in TPBS, washed in TPBS, and the peroxidase activity developed with Sigma Fast 3,3Ј-diaminobenzidine tablets (DAB) according to the supplier's instructions. Cytokeratin (Dako Z0622; diluted 1:100 in GBT) or RALDH2 (gift from Drs. P. McCaffery and U. Drä ger; diluted 1:5000 in GBT) expressions were studied in 10-m paraffin sections following the same protocol. Caldesmon (gift from Dr. Gourdie) and alpha-smooth muscle cell actin (Sigma A-2547) stainings in normal control (nonchimeric) or chimeric embryos were performed in both cryostat or paraffin sections following the immunofluorescence protocol described below.
For double antigen colocalization, cryostat (QCPN/WT1; QCPN/RALDH2) or paraffin sections (QCPN/cytokeratin; QCPN/ RALDH2; QCPN/caldesmon; QH1/caldesmon; vimentin/RALDH2; vimentin/cytokeratin: MF20/cytokeratin) of the proepicardial chimeras were used. Cryostat sections were obtained and processed as described for WT1. The first labeling step was an overnight incubation at room temperature of the sections in the monoclonal antibodies (QCPN undiluted, QH1 diluted 1:200 in GBT, antivimentin 1:75 in GBT, and MF20 1:20 in PBS; all obtained from the Developmental Studies Hybridoma Bank). After three washes in PBS, monoclonal antibody labeling was detected by using sheepanti-mouse biotinylated antibody (Amersham RPN-1001; 1:100 in PBS, 2 h, room temperature), washed again (3 ϫ 10 min, PBS), and incubated in extravidin-FITC (Amersham RPN-1232). After washing in PBS (3 ϫ 10 min), the sections were then incubated overnight at room temperature in polyclonal antibodies (anti-WT1 1:50 in PBS, anti-cytokeratin 1:100 in PBS, anti-caldesmon 1:100 in PBS, and anti RALDH2 1:5000 in PBS). Then, 3 ϫ 10 min PBS washes were followed by an incubation (2 h, room temperature) with a goat-anti-rabbit antibody (AlexaFluor-568, Molecular Probes). After extensive washes, the sections were mounted in 1:1 PBS/glycerol solution and analyzed by using a BioRad MRC 1024 laser scanning confocal microscope. In some of the figures, the caldesmon expression (goat-anti-rabbit Alexa Red 568 detected with the 605-nm wave-length filter on the confocal microscope) is shown in purple to improve signal/noise ratio.
Proepicardial Blocks and Proepicardial Ablations
Proepicardial block. To block attachment of the proepicardium to the heart, the eggshell membrane technique (Mä nner, 1993) was used. Chick embryos were incubated until stages H/H16 -H/H17. Openings in the vitelline and chorionic membranes were created by using tungsten needles. A small piece of eggshell membrane was inserted between the sinoatrial sulcus and the caudal vitellin veins, thus temporarily preventing the heart to be covered by epicardium.
Proepicardial ablation. The ablation was performed by excising the proepicardium of chick embryos at stages H/H16 -H/H17 using fine dissecting tungsten needles.
After the surgical procedure, blocked or ablated embryos were reincubated for 96 -120 h (resulting in H/H25-H/H27 embryos), 132-144 h (resulting in H/H28 -H/H29 embryos), or 180 -216 h (resulting in H/H32-H/H35 embryos). The embryos were fixed in modified Amsterdam's fixative, embedded in Paraplast Plus, sectioned on a microtome (5 m), and stained with hematoxylineosin or processed for immunohistochemical staining. In addition, some of the blocked or ablated embryos used for WT1 characterization were frozen in liquid nitrogen-cooled isopentane, sectioned in a cryostat, and immunostained for WT1.
RESULTS

Spatiotemporal Expression Patterns of WT1, Cytokeratin, and RALDH2 (Fig. 1)
Wilms' Tumor Expression
In the stages that precede epicardial development, WT1 expression is restricted to the proepicardium and to the coelomic epithelium that constitutes the developing parietal pericardium (data not shown; see also Carmona et al., 2001) . At the end of stage H/H17, the proepicardium attaches to the heart and spreads over the myocardium, forming the epicardial layer which strongly expresses WT1. Around stage H/H18, the first mesenchymal cells can be seen in the subepicardial space of the areas covered by epicardium. These cells first appear in the AV groove and at the end of stage H/H19 (Fig. 1A) in the CV groove and ventricular region. Virtually all early subepicardial mesenchymal cells (EPDCs) are WT1-positive. As epicardial development proceeds, WT1 expression is found in the epicardium that covers the cardiac chambers. In stages H/H20 -H/H26, the number of mesenchymal cells increases in the subepicardial space of the AV groove, CV groove, and the subepicardium of the ventricles (Figs. 1D and 1G ). In these junctional regions, a gradient in WT1 expression is evident. Within the AV subepicardium, the EPDCs closer to the epicardium express more WT1 than those located closer to the myocardium (Fig. 1D) . At stages H/H25-H/H26, the first WT1-positive cells can be seen invading the ventricular myocardium. No WT1-positive mesenchymal cells can be detected in the atrium (Fig. 1D) . WT1 continues to be expressed in the epicardium and subepicardial cells during later stages of development (H/H27-H/H33). At these stages, the number of WT1-positive intramyocardial cells within the ventricular myocardium increases significantly. Most of the WT1-positive cells are found in the outer (compact) myocardial layer, whereas only a few WT1-positive cells can be found in the inner trabecular layers of the myocardium (Fig. 1J ).
RALDH2 and CK Expression
The expression patterns obtained with the anti-CK and the anti-RALDH2 antibodies are similar. During early stages of epicardial development (H/H17-H/H19), the proepicardium and the developing epicardial layer strongly express RALDH2 and CK (Figs. 1B and 1C) . The subepicardial mesenchyme of the ventricles is scarce and seems to be organized as a single cell layer. Subepicardial mesenchymal cells are absent from the atrium. During stages H/H20 -H/ H26, both RALDH2 and CK are expressed in the subepicardial mesenchymal population. RALDH2 and CK display the same characteristic gradient of expression described for WT1. The difference in expression between the outer and inner subepicardial layers is higher for RALDH2 than for CK (Figs. 1E and 1F) . At the end of stage H/H26, a number of RALDH2/CK-positive cells can be seen in the compact myocardial layer of the ventricles ( Fig. 1H and 1I ), but not in the atrial or outflow tract myocardium. At stages H/H27-H/H33, the RALDH2 and CK expression in the epicardium is strong, but in most subepicardial cells and mesenchymal cells infiltrating the myocardial layers, the level of expression is weak or undetectable (Figs. 1K and 1L ).
Quail-Chick Chimeras (Fig. 2)
Quail-chick chimeras were prepared by transplanting proepicardium from quail origin (Figs. 2A and 2AЈ) into a chick host by using a piece of eggshell membrane (Fig. 2B ). This procedure not only allows the quail epicardium to populate the chick heart, but it also prevents the attachment of the chick proepicardium to the heart (Fig. 2B) .
The epicardium formed on the myocardial surface of the chick hosts in the quail-chick chimeras was QCPNpositive, indicating a donor (quail) origin (Figs. 2BЈ and 2BЉ) . The subepicardial mesenchymal cells were also QCPNpositive (Figs. 2BЈ, 2BЉ, and 2CЈ) . A subset of these QCPNpositive cells contribute to the formation of subepicardial coronary vessels (Fig. 2CЈ) . Around stages H/H25-H/H26, QCPN-positive cells start to migrate into the ventricular wall. From stages H/H28 -H/H29 onward, QCPN-positive cells are found throughout the ventricular wall, some quail cells even being observed in the endocardial lining of the developing ventricular trabeculae (Fig. 2BЈ ). In the AV junction, QCPN-positive cells start to invade the myocardium at stages H/H29 -H/H30, at which stage sporadic QCPN-positive cells are also observed in the endocardial cushions. A considerable number of QCPN-positive cells are detected in the cushions around H/H31-H/H32 (Fig.  2CЉ) . It is important to note that QCPN-expressing immigrating cells were never observed in the atrial myocardium (Fig. 2BЈ) or the outflow tract (data not shown).
Molecular Phenotype of the Epicardial-Derived Cells in the Quail-Chick Chimera (Figs. 3 and 4)
QCPN-positive (i.e., quail-derived) epicardial and subepicardial cells show the same molecular phenotype as described for the normal epicardium and its derivatives (see A subset of epicardial and subepicardial QCPN-positive cells in the chimeras also express caldesmon. These cells are specifically found in the AV and CV grooves related to the developing media of the subepicardial coronary arteries. (Figs. 4A and 4B) . Interestingly, some of the QCPN-positive cells found in the AV endocardial cushions express caldesmon as well (Figs. 4D-4F ). The majority of the caldesmonexpressing cells are located in the subendothelial layer of the cushions, although some weakly caldesmon-expressing QCPN-positive cells are found in the core of the cushions. F) . The pericardial tissue, which is strongly expressing WT1, is QCPN-negative and not derived from quail donor tissue, (red dots). Bars, 33 m. AM, atrial myocardium; AVM, atrioventricular myocardium; EN, endocardium; EP, epicardium; LI, liver; MYO, myocardium; PE, pericardium; SE, subepicardium; VM, ventricular myocardium.
FIG. 4.
EPDCs differentiate into a smooth muscle cell(-like) phenotype. In (A) and (B), the formation of coronary vessels from the quail proepicardial explant is shown in a stage H/H36 chimera. In (A), QCPN-labeled EPDCs (green nuclei) are found in the subepicardium and myocardium (arrowheads), and in endothelium (double arrowhead) and media of the coronary vessels. The smooth muscle cells express the smooth muscle antigen caldesmon (red staining, arrows). Bar, 33 m. In (B), another detail from the same chimera is presented. Quail-derived vascular cells have been stained with the QH1 antibody (green), while smooth muscle cells appear in red (caldesmon expression, arrow). Note the presence of vessels of small caliber that have not developed a muscular wall (QH1 red labeling, arrowheads). Bar, 33 m. The image in (C) shows smooth muscle cell ␣-actin expression in the AV cushions of an H/H29 chimera. Arrows indicate
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The caldesmon expression pattern coincides with the expression pattern of smooth muscle alpha-actin (Fig. 4C) .
Proepicardial Block and Proepicardial Ablation (Figs. 5 and 6)
Proepicardial block experiments result in different phenotypes as compared with those obtained by a direct proepicardial ablation.
The proepicardial block experiments generally do not prevent the formation of the epicardium, but rather cause a general delay in the process. This is a result of the fact that the proepicardium will often grow around the blocking eggshell membrane to reach the myocardial surface of the heart. Proepicardial ablation prevents epicardial development for 12-24 h; after that period, a compensatory mesothelial proliferation often develops in the original proepicardial location and initiates the development of an epicardial-like tissue.
The cardiac phenotype observed after blocking experiments ranges from almost normal to severely abnormal (Figs. 5A and 5B). The abnormalities, most of them typically observed from stages H/H27-H/H28 onward, include localized or severe reduction of the thickness of the compact ventricular myocardium (Figs. 5A-5D ), small gaps in myocardial continuity (Fig. 5E) , and occasionally pouch-like myocardial interruptions (Fig. 5F ) where the ventricular lumen is contiguous with the subepicardial space/ subepicardial vascular structures (Fig. 5F ). These small and large disruptions in the myocardial continuity sometimes result in subepicardial bleeding (hemorrhage) (Figs. 5D-5F ). The malformations also include abnormalities of the coronary system (see Discussion). Another characteristic feature of the proepicardial blocked embryos was valvuloseptal dysmorphogenesis. This was particularly prominent in the older embryos examined (H/H35). The AV cushions of these experimental embryos were much larger than those of the controls (Fig. 5B, compare with Fig. 5A ).
Compared with the blocked embryos, the cardiac abnormalities seen in proepicardial ablated embryos (Figs. 6B and 6C) are more severe and are present at earlier stages of development. These abnormalities frequently include wide myocardial pouch-like discontinuities, similar to those that were occasionally seen in the blocked specimens (see above) and which form endocardial-subepicardial connections (Fig. 6C) , and occasionally malformations of the ventricular septum (Fig. 6B) . In addition, the formation of AV endocardial cushion tissue is also abnormal. Compared with normals (Fig. 6A) , the AV cushions in ablated embryos extend deeper into the ventricular segments (Fig. 6B) . It is important to note that most of the ablated embryos died around stage H/H31, i.e., the stage that the coronary subepicardial plexus connects to the circulation. A few ablated embryos, however, survived up to stage H/H34 -H/H35. (Fig. 7) and Blocked Embryos (Fig. 8) As mentioned above, proepicardial ablation is followed by the generation of a compensatory (pro)epicardial-like tissue (Fig. 7A ), which eventually migrates over the myocardial surface of the heart. This migration is delayed (i.e., the epicardial-like tissue arrives later) and incomplete (i.e., some areas do not become covered at all). In addition, in the limited subepicardial space that is formed in those areas that are covered, only very few subepicardial cells can be found. The myocardial wall in the ablated embryos that is not covered by the epicardial-like tissue is considerably thinner than the myocardial wall in the areas covered with this tissue (Fig. 7B) . The walls in these specimens frequently show myocardial indentations and/or interruptions (Fig. 7C) .
Molecular Characterization of the Phenotype of Proepicardial Ablated
At stage H/H26 -H/H27, the pouch-like structures that bulge out from the ventricular lumen protrude into the subepicardium for 100 -200 m. The pouches are lined with vimentin-positive endothelial cells. These cells, however, do not express epicardial markers such as CK and RALDH2. These epicardial markers, however, are expressed in the subepicardial tissues surrounding the pouches (Figs. 7D and  7E ). In the embryos that survived up to stage H/H34 -H/ H35, the subepicardial tissues adjacent to the endothelial lining of the pouches undergo compaction to form a multilayered wall. Within this wall, the cell layers closest to the endothelium express caldesmon (Fig. 7F) .
The AV cushions in experimental embryos are malformed (see Figs. 5 and 6). The expression of SMA in the endocardial AV cushions of control and proepicardial ablated specimen at H/H31 is shown in Figs. 7G and 7H. No significant difference in the level of SMA expression was observed.
In the blocking experiments, scarce and discontinuous epicardium was found. The flattened epicardium covered a thin subepicardial space in which only a few CK-positive subendocardial areas of strong expression. Bar, 65 m. (D-F) The presence of donor-derived EPDCs in the AV cushions of the same chimera illustrated in (C). EPDCs appear as green dots (QCPN nuclear staining); some of these cells coexpress the smooth muscle lineage-related marker caldesmon (purple). (D) Some of these EPDCs are caldesmon-positive (arrows) while others, located in the core of the cushions, are caldesmon-negative (arrowheads). Bar, 65 m. (E) The tendency of the EPDCs to accumulate in the subendothelial layers of the AV cushions (arrowheads), where their caldesmon expression seems to be stronger. Bar, 22 m. In (F), EPDCs migrating into the cushions from the myocardium are shown. Arrowheads point to caldesmon-negative EPDCs, while the arrow indicates the presence of caldesmon expressing EPDCs. Bar, 33 m. B, blood; CM, cushion mesenchyme; EN, endocardium; EP, epicardium; MYO, myocardium; SE, subepicardium. and RALDH2-positive mesenchymal cells were seen. This abnormal epicardium/subepicardium usually covered a "thinned" myocardial area (Figs. 8B-8D ). The number of intramyocardial RALDH2-and WT1-positive cells in the experimental embryos was also reduced when compared with controls (Figs. 8A-8D) .
DISCUSSION
There is a growing body of evidence that the epicardium is of great importance for general cardiac development. As already indicated, experimental manipulation of epicardial growth (i.e., microsurgery) as well as genetic perturbation (i.e., knock-out technology) of molecules involved in epicardial cell behavior (e.g., migration, differentiation) have been reported to disrupt normal development of the heart, resulting in coronary and myocardial dysmorphogenesis (Dyson et al., 1995; Kwee et al., 1995; Yang et al., 1995; Moore et al., 1999; Wu et al., 1999; Gittenberger-de Groot et al., 2000; Tevosian et al., 2000) and general cardiac defects involving endocardial cushion tissues and septal structures (Gittenberger-de Groot et al., 2000; Pé rezPomares et al., 2001) . Most of the knock-out mice die in utero around ED12-ED13 due to a severe pericardial bleeding and/or cardiac failure caused by thinning of the myocardial wall. Thus, interference with epicardial development leads to abnormalities in the formation of superficial and internal cardiac structures.
The epicardial epithelium only covers the outer surface of the heart. Initially, it was difficult to understand how defective epicardial development could generate such a wide spectrum of cardiac malformations. Recent studies, however, have shown that the epicardium generates a population of epicardially derived cells (EPDCs) that invades the heart tissues in a well-defined spatiotemporal manner, reaching the subepicardial, myocardial and valvuloseptal tissues (Pé rez-Pomares et al., 1997 , 2001 Dettman et al., 1998; Gittenberger-de Groot et al., 1998; Mä nner, 1999) . It has been established that EPDCs differentiate into coronary smooth muscle cells, cardiac fibroblasts, and coronary endothelium (Mikawa and Fischman, 1992; Pé rez-Pomares et al., 1997 Dettman et al., 1998; Gittenberger-de Groot et al., 1998; Mä nner, 1999) . Very little information was available about the invasive population of EPDCs in terms of their timing of migration, range of distribution, and expression of epicardial markers. In this study, we show the normal distribution of EPDCs combining a cell-tracing system (quail-to-chick chimeras) with immunohistochemical molecular characterization using epicardial and differentiation markers.
EPDCs Invasion of Developing Cardiac Tissues
Our findings show that a population of EPDCs invades the subepicardial space as well as the ventricular myocardium, the AV myocardium, and the AV endocardial cushions approximately between the stages H/H28 -H/H29. The epicardial epithelium expresses the transcription factor WT1 and the RA-synthesizing enzyme RALDH2. The subepicardial mesenchymal EPDCs also express both markers. However, as soon as they migrate into the myocardium, a process that starts around H/H26, RALDH2 expression is reduced significantly. The level of expression of WT1 in the EPDCs then gradually decreases as the cells invade deeper into the myocardial wall. Thus, the EPDCs found in the AV endocardial cushions, many of which express caldesmon, do not express RALDH2 or WT1. In addition, the terminally differentiated coronary endothelium of EPDC origin (subepicardial as well as intramyocardial), which is characterized by the expression of the endothelial specific marker QH1 (in quail), generally does not express WT1 or RALDH2. Therefore, the loss of expression of WT1 and RALDH2 is related to the organization of EPDCs in recognizable structures and the upregulation of molecular markers of cell lineage-specific differentiation. When we delay epicardial development, a decrease in the overall number of EPDCs, and hence also the number of WT1/RALDH2-positive cells, is observed. This reduction in the number of cells correlates with malformations of the structures in which they are normally found. These malformations include the "thin myocardial syndrome," abnormal coronary vessels, and dysmorphic AV cushions. This spectrum of malformations closely resembles that seen in mice deficient for genes involved in epicardial development (Dyson et al., 1995; Kwee et al., 1995; Yang et al., 1995; Moore et al., 1999; Wu et al., 1999; Tevosian et al., 2000) .
EPDCs-Myocardial Interaction: A Possible Role for WT1 and RALDH2 in the Formation of the Compact Layer of the Myocardial Wall
The invasion of the ventricular myocardium by EPDCs (stages H/H25-H/H26) coincides with the onset of the myocardial thickening that leads to the generation of the compact layer of the ventricular wall. As mentioned above, at this point, the EPDCs are expressing WT1 and RALDH2. There is reason to believe that this expression is related to a specific role for EPDCs in myocardial development. WT1 encodes a zinc-finger transcription factor (Call et al., 1990; Gessler et al., 1990) which is involved in a large number of normal functions for cell proliferation, differentiation, and survival (Armstrong et al., 1993) . However, the precise function of WT1 in normal vertebrate development is not yet established. It is interesting to note that, in the WT1 k.o. mouse, all the organs that normally harbor an invasive population of WT1-positive cells (i.e., kidneys, gonads, adrenals, spleen, cardiac ventricle) either are absent or are abnormally developed (Moore et al., 1998 (Moore et al., , 1999 . It is important to emphasize that the ventricular phenotype of the WT1 k.o. mouse is virtually identical to that of the VCAM1 k.o. and alpha-4-integrin k.o. mouse, mice that lack a normal epicardium. Embryos of these three k.o. models die due to cardiac failure likely caused by ventric- A and B] . The AV valves in the experimental embryo are dysplastic and the interventricular septum (IVS) looks underdeveloped and poorly compacted. The arrowheads indicate the presence of abnormal trabeculation (cf. A) Bar, 700 m. In (C), a detail of the compact myocardial layer of the right ventricle in a control embryo is shown. The thickness of the compact myocardium is indicated by the double-headed arrow. Bar, 25 m. In (D), the myocardium of an experimental embryo is shown at the same magnification. The double-headed arrows indicate the reduced thickness of the compact myocardium, around one-fifth of the one in the control. Bar, 25 m. In (E), a higher magnification of the myocardium of a proepicardially blocked embryo is presented. The arrow points to a myocardial discontinuity in the thin compact layer. Blood accumulates in the subepicardial area as indicated by arrowheads. Bar, 50 m. In (F), a pouch-like structure is shown. The lumen of the pouch is connected with the endocardium (asterisk) and its wall is formed by numerous cells that present a smooth muscle-like phenotype (arrowheads). Accumulation of blood in the subepicardium is indicated by an arrow. Developing subepicardial vessels are often found in relation with the pouches (double arrowhead). Bar, 100 m. EP, epicardium; IVS, interventricular septum; LA, left atrium; LV, left ventricle; MYO, myocardium; PE, pericardium; RV, right ventricle; RA, right atrium; SE, subepicardium. ular myocardial hypoplasia around ED13 (Kwee et al., 1995; Yang et al., 1995; Moore et al., 1999) . At this developmental stage, the coronary system is not yet functional (i.e., not connected to the general systemic circulation). This implies that myocardial hypoplasia can not be a direct result of reduced blood supply from defective coronary arteries. Taken together, these observations strongly suggest that the observed myocardial phenotype is caused by abnormal epicardial development. As discussed above, RALDH2 and WT1 are expressed in mouse and avian epicardial and epicardially derived cells. Reducing/abolishing the expression of WT1 within the primitive myocardial wall, either by genetic means (WT1 k.o.) or by reducing the number of cells that express WT1 in the wall (i.e., experimental perturbation of epicardial development), leads to basically the same cardiac phenotype. The most characteristic feature in this respect is the thin myocardial wall. Therefore, we conclude that WT1 expressed by the intramyocardial EPDCs plays a crucial role in the formation of the thick compact layer of the ventricular myocardial wall. In this respect, it is interesting to note that during normal development the myocardial layer of the atrium, that remains thin through development, does not get invaded by EPDCs.
WT1-positive epicardial and epicardially derived cells also express the RA-synthesizing enzyme RALDH2. It is interesting to note that in humans the WT1 transcription factor downregulates the RAR-alpha gene (Goodyer et al., 1995) and that the phenotype of the WT1 k.o. mouse closely resembles that of the RA-depleted (Wilson et al., 1953) and RXR-alpha k.o. mice (Sucov et al., 1994) . Depletion of RA from the diet is known to severely disturb heart development, causing hypoplasia of the ventricles ("thin myocardium"), a phenotype that is also seen in RXR-alphadefective mice. Furthermore, ventricular expression of the myosin light chain 2a (MLC-2a) gene is abnormally persistent in RXR-alpha-deficient embryos. This fact can be considered both as retardation in ventricular maturation or as misspecification of the ventricle into an atrial fate (Dyson et al., 1995) . However, other authors have suggested that, in the absence of proper retinoid signaling, cells might precociously reach a state of terminal differentiation (Kastner et al., 1994 (Kastner et al., , 1997 .
Proepicardial block results in a decreased amount of WT1-positive, RALDH2-positive intramyocardial EPDCs, and myocardial abnormalities, including areas of thin compact myocardium, gaps in the myocardial layers, and dysmorphic AV valvuloseptal tissues. Myocardial defects were commonly seen in areas that would normally be covered by epicardium during the first hours of epicardial development (i.e., in the inner curvature AV, CV, and ventricular areas). Thus, it is likely that the abnormal myocardial development is directly related to the reduction of the numbers of intramyocardial EPDCs in experimental embryos. A possible role for epicardial cells in the regulation of cardiomy- ocyte differentiation was also indicated in studies where epicardial cells were cocultured with isolated cardiomyocytes (Eid et al., 1992) . In these studies, it was shown that when cultured in the presence of epicardial cells, isolated ventricular myocytes express more ventricular myosin heavy chain and form myofibrillar arrays that are more organized than those in cells that were not cultured in the presence of epicardial cells. It is important to realize that these observations were made years before it became clear that the epicardium gives rise to a subpopulation of highly invasive cells that populate several structures of the developing heart, including the ventricular myocardial wall (Dettman et al., 1998; Gittenberger-de Groot et al., 1998; Mä nner, 1999) .
EPDCs, Coronary Vasculature, and Pouch-Like Structures
Proepicardial block or ablation does not prevent the myocardium from becoming covered by "epicardial-like" tissue. In the proepicardial block, this tissue might derive from the original proepicardium as a result of late proepicardial attachment to myocardium (usually heterotopic resulting from the experimental manipulations). This tissue has been described as a secondary sinu-ventricular mesocardium by Mä nner (1993) . In the ablation experiments, the epicardial-like tissue likely derives from coelomic epithelium in the vicinity of the original proepicardium. All the mesothelium of the region is highly proliferative as shown by BrdU incorporation (data not shown). Removal of the main mass of proepicardial tissue does not seem to prevent the growth of a new proepicardiallike structure. It is important to clarify that the tissue in both the normal proepicardia and compensatory structures found after ablation are of mesothelial nature, i.e., derivatives of the coelomic epithelium and not of the sinus venosus myocardium or of the hepatocytes of the liver primordium.
The "epicardial-like" tissue in proepicardial block and ablation locally produces "EPDCs" through EMT, albeit that the overall number of these cells in the subepicardium is considerably lower than that seen in normal hearts. In addition, in our experimental embryos, coronary development was found to be perturbed. These abnormalities included widening of coronaries and ectopic location of larger vessels. We did not perform a detailed study of coronary development in normal and epicardially perturbed hearts in the context of this paper. However, this aspect is the focus of a forthcoming study.
The alterations of coronary vessel formation was accompanied by the formation of pouch-like structures that appear to be ectopic endocardial sinusoids. Our data suggest that direct contact between endocardium and subepicardial tissues cause massive differentiation of EPDCs into the smooth muscle cell lineage, which leads to the formation of a "media-like" cell layer. This is in accordance with the role that the endothelium plays in recruitment and differentiation of perivascular/smooth muscle cells (Hungerford and Little, 1999) , a process that is apparently regulated by PDGF-BB secretion (Carmeliet, 2001) .
The pouch-like structures resemble the conotruncal abnormalities found in the connexin43 k.o. mouse (Reaume et al., 1995; reviewed in Lo, 1999) . Interestingly, recent observations suggest that this particular phenotype might (partially) be caused by an alteration in epicardial migration in the conoventricular region of the heart (Li et al., 2002) . In this respect, it is important to note that there is a growing body of evidence that outflow tract epicardium might be partly derived from coelomic epithelium at the anterior pole of the heart (Pé rez- .
EPDCs in the Endocardial Cushions. A Link to the Coronary Smooth Muscle Cell Lineage
EPDCs in the AV endocardial cushions express the smooth muscle cell-related markers caldesmon and alpha smooth-muscle actin (␣SMA). Both markers are also detected in EPDCs from the subepicardium, where EPDCs contribute to the formation of the media of the developing coronary arteries. Caldesmon expression is not abundant in the myocardial layers, though it can be found in some scattered cells in close relation to the developing coronary endothelium. It appears that the expression of caldesmon in EPDCs is related to the proximity of these cells to the endothelium. Although the endocardial cushions are known to lack smooth muscle cells, a population of valvular interstitial cells, which present an intermediate phenotype between fibroblasts and vascular muscle cells, has been described in mammals (Filip et al., 1986) . The embryonic origin and role of these cells, which are coupled and innervated by motor nerve endings, are not clear. Here, we present data that at least a subset of these progenitors of these valvular interstitial cells could be EPDCs that have invaded the endocardial cushions. These valvular EPDCs seem to have (at least partially) gone through the same differentiation events as the EPDCs that form the coronary smooth muscle cells (Mikawa and Gourdie, 1996; Landerholm et al., 1999; Vrancken Peeters et al., 1999; Lu et al., 2001) . Given the abnormalities observed in the experimental embryos, one can speculate that valvular EPDCs form an important role in the development of these structures. However, when we compared smooth muscle cell marker expression in valvuloseptal tissue of control and experimental specimens (Figs. 7G and 7H ), we did not find a significant difference in expression in comparable regions. In this respect, it is noteworthy that it is well documented that SMA is also expressed in cushion mesenchymal cells after undergoing endocardial-to-mesenchymal transformation (Nakajima et al., 1997 (Nakajima et al., , 1998 Ramsdell and Markwald, 1997) . Hence, it is likely that the expression of smooth muscle cell markers in cushion mesenchymal cells is a result of both differentiation events, and that the SMA/ caldesmon-positive cells that we detect immunohistochemically in sections can be endocardially as well as epicardially derived. The fact that we did not observe a difference in the expression of smooth muscle cell markers in the endocardial cushion tissues of control vs proepicardial ablated embryos leads to a number of hypothetical mechanisms. First, the migratory behavior of EPDCs in proepicardial ablations (hence tissue derived from the compensatory tissue) could be altered compared with that of EPDCs (derived from the proepicardium) in control hearts.
In this scenario, it is possible that subsets of EPDCs do arrive in the cushions but not in the same time frame and/or number. It is also possible that the EPDCs in the cushions are involved in controlling endocardial-tomesenchymal transformation similar to the proposed mechanism for the regulation of developing endothelium by perivascular cells/pericytes through the tie2/Ang1 system (Suri et al., 1996; Maisonpierre et al., 1997) . If this is , a picture of the same region at the same magnification in an ablated embryo is presented. The WT1 expression (red nuclei) is normal in the pericardium (PE, positive control) as compared with the same tissue in (A). However, the amount of WT1-positive cells in the delayed epicardium is low (arrowheads, compare with A) and WT1-reactive EPDCs are almost absent from the myocardial layers. Note that the thickness of the compact myocardium of the area is at least one-half of that of the normal myocardium (double-headed arrows in A and B). Bar, 45 m. In (C), a confocal image of a RALDH2-stained H/H27 chick embryo is shown. The red cytoplasmic labeling is found in the epicardium (EP) as well as in some mesenchymal cells in the myocardial layers (arrowheads). Bar, 90 m. In (D), a detail of an H/H27-blocked embryo is presented. The RALDH2 expression in the epicardium is more heterogeneous, with areas of very weak expression. RALDH2-positive cells are not found in the myocardium. Bar, 90 m. BW, body wall; EP, epicardium; MYO, myocardium; PE, pericardium; SE, subepicardium. the case, a change in the number of EPDCs in the cushions, or the temporal window in which the EPDC invade the cushions, would not only alter the EPDC-related SMA expression, but would at the same time also perturb the endocardially derived SMA-positive population.
CONCLUSION
We conclude that all or at least most of the subepicardial mesenchymal cells are EPDCs as suggested by their expression of WT1 and RALDH2 in an early stage. These markers seem to disappear from most EPDCs as they differentiate into other cell lineages, such as fibroblasts, vascular smooth muscle, and endothelial cells (Dettman et al., 1998; Gittenberger-de Groot et al., 1998; Pé rez-Pomares et al., 1998) . The nondifferentiated cells, which continue to express WT1 and RALDH2, invade the ventricular myocardium. It is tempting to speculate that EPDC-RALDH2-mediated synthesis of RA is an effective way to locally release RA within the developing ventricular layers. We suggest that the developmental process that leads to ventricular myocardium compaction is dependent on the invasion by retinoid-producing EPDCs. It is plausible that the first wave of RA-producing EPDCs invading the ventricular myocardium plays a role in the induction of downstream molecules involved in myocardial maturation. One of these downstream targets could be IGF-2 (Vincent et al., 1996) , a mitogen which is involved in the thickening of the myocardium (Liu et al., 1996) . The role played by WT1 in the development of the myocardial wall might be to maintain the EPDCs in an undifferentiated, RA-producing state. The inactivation of this gene would cause premature differentiation of the EPDCs, resulting in the downregulation of RA production. This hypothesis is supported by the "thin myocardium" syndrome reported for the WT1-k.o. and RXR-alpha-k.o. mice.
EPDCs were never observed in the myocardial walls of atria and OFT. In itself this is not surprising as the epicardial epithelia of atria and OFT do not undergo EMT to generate a population of subepicardial EPDCs (Pé rez- Pomares et al., 1997) . In line with the above hypothesis about the role of EPDCs in myocardial development, the myocardial walls of the atria and OFT do not thicken over time but instead remain thin. It is possible that the absence of EPDCs in atria and OFT is a result of differences in intrinsic properties between the atrial/OFT myocardium and the ventricular myocardium. It is also possible, but less likely, that these phenomena are resulting from intrinsic differences in the epicardial epithelium covering these segments.
The presence of numerous EPDCs in the AV valves, combined with the observation that proepicardial block/ ablations impair AV valve development, suggest an important role for EPDCs in valvuloseptal morphogenesis. Given the fact that the only other tissue types in the AV valves are endocardial and endocardially derived mesenchyme, one has to assume that proper interaction between EPDCs and these cells is imperative for correct valve formation. The developmental mechanisms involved are yet to be elucidated but could involve regulation of endocardial EMT, regulation of cell division and cell death (cf. Lakkis and Epstein, 1998) , regulation of cell migration, and regulation of extracellular matrix production.
In summary, we suggest that EPDCs not only materially contribute to the different tissues of the heart (i.e., coronary endothelium/smooth muscle, interstitial fibroblasts, and cushion mesenchyme), but that they also have a critical function in the differentiation of the ventricular myocardium and the AV valves.
